ClinicalTrials.gg
TerminatedNCT04515394Updated Dec 22, 2022Results posted

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

A Phase 2 interventional study of Tepotinib and Cetuximab in Colorectal Neoplasms, sponsored by EMD Serono Research & Development Institute, Inc.. Terminated at 67 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-22.

Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated early due to operational challenges identifying suitable participants for screening in the study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
178th of 185
3 · median 60
Started
2021
with 5 others
Phase 2
107 of 187
20 open now
Registered
136th of 187
by date

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 178th largest by enrollment of the 185 interventional ones that give a count, is one of 6 that started in 2021, is one of 107 in phase 2, and was the 136th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study was to assess the preliminary antitumor activity, safety and tolerability of tepotinib in combination with cetuximab in participants with RAS/BRAF wild-type left-sided Metastatic Colorectal Cancer (mCRC) having acquired resistance to anti-epidermal growth factor receptor (EGFR) antibody targeted therapy due to mesenchymal epithelial transition (MET) amplification.

03

Conditions studied

  • Colorectal Neoplasms

Keywords

  • Colorectal cancer
  • RAS wild-type
  • Tepotinib
  • Cetuximab
  • Erbitux
  • Epidermal growth factor receptor resistance
  • Hepatocyte growth factor
  • Panitumumab
  • Mesenchymal epithelial transition
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced (locally advanced or ) left sided (from splenic flexure to rectum - National Comprehensive Cancer Network [NCCN] version 4.2020) colorectal cancer (CRC) with RAS/BRAF wild-type at study entry confirmed prior to enrollment, with previous anti-epidermal growth factor receptor (anti-EGFR) therapy and acquired resistance on the most recent anti-EGFR monoclonal antibody therapy (panitumumab or cetuximab) by radiological documentation of disease progression according to Version 1.1
  • Mesenchymal epithelial transition (MET) amplification detected by a positive liquid and/or tissue with appropriate regulatory status (collected after disease progression of the previous anti-EGFR therapy)
  • by Investigator in accordance with RECIST Version 1.1
  • Performance Status (ECOG PS) of 0 or 1
  • greater than 3 months
  • Participants having at least one systemic treatment for mCRC including 1 anti-EGFR monoclonal antibody therapy as the most recent for mCRC before study treatment and must have shown a radiologically confirmed by RECIST Version 1.1 complete response (CR) or partial response (PR), both for at least 4 months or stable disease (SD) for at least 6 months to that therapy prior to disease progression
  • Less than 2 months between the last administration of the most recent EGFR containing regimen and first dosing in this study
  • Adequate hematological function, hepatic and renal functions as defined in the protocol
  • Signed and dated indicating that the participants had been informed of all the pertinent aspects of the trial prior to enrollment
  • use by males or females will be consistent with local regulations on contraception methods for those participating in clinical studies
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Participants with symptomatic central nervous system (CNS) who are neurologically unstable or have required increasing doses of within the 2 weeks prior to study entry to manage . Also excluded are participants with carcinomatous meningitis
  • Participants who have brain metastasis as the only
  • Prior chemotherapy, biological therapy, radiation therapy, hormonal therapy for anti-cancer purposes, targeted therapy, or other anticancer therapy (not including palliative radiotherapy at focal sites) within 21 days prior to the first dose of study intervention, except for the anti-EGFR containing regimen including associated chemotherapy if applicable, which may be continued until enrollment of the participant in the study
  • Any unresolved toxicity Grade 2 or more according to the National Cancer Institute- (NCI-CTCAE) Version 5.0, from previous anticancer therapy excluding neuropathy, alopecia and rash
  • Severe reactions to monoclonal antibodies (Grade greater than or equal to [>=] 3 NCI-CTCAE v 5.0), any history of anaphylaxis, or uncontrolled asthma (i.e., 3 or more occurrences of partially controlled asthma)
  • Discontinuation of the most recent cetuximab or panitumumab containing therapy due to an adverse event
  • Prior treatment with other agents targeting the hepatocyte growth factor (HGF)/Mesenchymal epithelial transition (MET) pathway
  • Impaired cardiac function: less than [\<] 45 percent [%] defined by echocardiography (a screening assessment not required for participants without a history of congestive heart failure unless clinically indicated); Serious arrhythmia; Unstable angina pectoris; heart failure Class III and IV; Myocardial infarction within the last 12 months prior to study entry and Symptomatic pericardial effusion; interval by Fridericia (QTcF) greater than (>) 480 milliseconds (ms)
  • Hypertension uncontrolled by standard therapies (not stabilized to less than [\< ]150/90 millimeter of mercury [mmHg])
  • History of neoplasm other than mCRC
  • History of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the test products
  • Known infection with , or an active infection with or virus
  • Major surgery within 28 days prior to Day 1 of study intervention
  • History of Interstitial lung disease (ILD) or interstitial pneumonitis including radiation pneumonitis that required steroid treatment
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Tepotinib + Cetuximab

    Drug: Tepotinib · Biological: Cetuximab

Interventions

  • Participants received Tepotinib film-coated tablets at a dose of 500 milligrams (mg) orally, once daily (QD) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.

    Also known as: MSC2156119J

  • BiologicalCetuximab

    Participants received weekly intravenous infusions of Cetuximab at a dose of 250 milligrams per square meter (mg/m\^2) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.

    Also known as: Erbitux®, MSB0010442D

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 5.0

    DLTs are defined as any of the following toxicities and judged by Investigator and/ Sponsor to be not attributable to the disease/disease-related processes under investigation: Grade 4 neutropenia for more than 7 days; Grade greater than or equal to \[\>=\] 3 febrile neutropenia with absolute neutrophil count \< 1000 per cube millimeter (per mm\^3) and a single temperature of \> 38.3 degree Celsius/a sustained temperature of \>= 38 degree Celsius for more than 1 hour; Grade 4/Grade 3 thrombocytopenia with non-traumatic bleeding; Grade 3 uncontrolled nausea/vomiting and/diarrhea that has not improved within 72 hours despite adequate and optimal treatment; Grade 4 vomiting and/diarrhea; Grade \>= 3 skin toxicity that has not resolved to Grade 2 after 14 days of adequate treatment; Any other Grade \>= 3 non-hematological AE will be defined as DLT. Exceptions are alopecia/an isolated lipase and/amylase elevation of Grade \>= 3 without clinical/radiological evidence of pancreatitis.

    Time frame: Day 1 to Day 21 of Cycle 1 (each cycle is of 21 days)

  2. Number of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigators

    OR is defined as a best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all target lesions.

    Time frame: Time from first study treatment assessed up to 218 days

Secondary outcomes

  1. Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigator

    For participants with objective response, DoR is the time from when the complete response (CR) or partial response (PR) (whichever is first) criteria are first met until progression disease (PD) or death due to any cause within the period of 2 scheduled tumor assessments (84 or 168 days) after the last tumor assessment, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: Time from the first dose of study drug until occurrence of PD, death due to any cause or last tumor assessment (assessed up to 218 days)

  2. Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigators

    PFS is defined as the time (in months) from first administration of study intervention to the date of the first documentation of progression disease (PD) or death due to any cause within the period of 2 scheduled tumor assessments (84 or 168 days) after the last tumor assessment, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was to be estimated using Kaplan-Meier (KM) plots.

    Time frame: Time from the first dose of study drug until occurrence of PD, death due to any cause or last tumor assessment (assessed up to 218 days)

  3. Overall Survival (OS) Assessed by Investigators

    OS is defined as the time (in months) from first administration of study intervention to the date of death. OS was to be estimated using Kaplan-Meier (KM) plots.

    Time frame: Time from first study treatment until death, assessed up to 218 days

  4. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events that started or worsened after first dose of study intervention until 30 days after last dose. TEAEs included both serious and non-serious TEAEs. Treatment-related TEAEs is defined as reasonably related to the study intervention.

    Time frame: Time from first study treatment up to 30 days after the last dose, assessed up to 226 days

  5. Number of Participants With Clinically Significant Changes From Baseline in Vital Signs

    Vital sign assessment included assessments of height, weight, temperature, pulse rate, respiratory rate, and blood pressure. Clinical significance was determined by the investigator. Number of participants who had any clinically significant changes from baseline in vital signs were reported.

    Time frame: Time from first study treatment up to 30 days after the last dose, assessed up to 226 days

  6. Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters

    Laboratory investigation included hematology, biochemistry, coagulation, routine urinalysis and other screening tests (Follicle-stimulating hormone (FSH) and estradiol, Serum or highly sensitive urine human chorionic gonadotropin (hCG) pregnancy test, Serology (HIV antibody, hepatitis B surface antigen \[HBsAg\], and hepatitis C virus antibody) and all of the safety labs were performed locally. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported.

    Time frame: Time from first study treatment up to 30 days after the last dose, assessed up to 226 days

  7. Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings

    12-lead ECG recordings included heart rate and measures PR, QRS, QT and QTcF intervals. 12-lead ECG recordings were obtained after the participants have rested for at least 5 minutes in semi-supine or supine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported.

    Time frame: Time from first study treatment up to 30 days after the last dose, assessed up to 226 days

  8. Number of Participants With At Least 1 Postive Anti-Drug Antibodies (ADAs) for Cetuximab

    Serum samples were analyzed by a validated electrochemiluminescence immunoassay method to detect the presence of antidrug antibodies (ADA). Number of participants with positive ADA were reported.

    Time frame: At Day 1 of cycle 1 (each cycle is of 21 days) and at End of Treatment (14 days after last dose, assessed up to 210 days)

07

Results

Posted Dec 22, 2022

Participant flow

Participant flow — Overall Study
MilestoneTepotinib + Cetuximab
Started3
Treated2
Completed2
Not completed1
Withdrew: Participant did not receive treatment1

Outcome measures

PrimaryNumber of Participants Who Experienced Dose Limiting Toxicities (DLTs) According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 5.0

DLTs are defined as any of the following toxicities and judged by Investigator and/ Sponsor to be not attributable to the disease/disease-related processes under investigation: Grade 4 neutropenia for more than 7 days; Grade greater than or equal to \[\>=\] 3 febrile neutropenia with absolute neutrophil count \< 1000 per cube millimeter (per mm\^3) and a single temperature of \> 38.3 degree Celsius/a sustained temperature of \>= 38 degree Celsius for more than 1 hour; Grade 4/Grade 3 thrombocytopenia with non-traumatic bleeding; Grade 3 uncontrolled nausea/vomiting and/diarrhea that has not improved within 72 hours despite adequate and optimal treatment; Grade 4 vomiting and/diarrhea; Grade \>= 3 skin toxicity that has not resolved to Grade 2 after 14 days of adequate treatment; Any other Grade \>= 3 non-hematological AE will be defined as DLT. Exceptions are alopecia/an isolated lipase and/amylase elevation of Grade \>= 3 without clinical/radiological evidence of pancreatitis.

Time frame:
Day 1 to Day 21 of Cycle 1 (each cycle is of 21 days)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 5.0
ParticipantsTepotinib + Cetuximab
Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 5.00
PrimaryNumber of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigators

OR is defined as a best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all target lesions.

Time frame:
Time from first study treatment assessed up to 218 days
Reported as:
Count of participants · Participants
Number of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigators
ParticipantsTepotinib + Cetuximab
Number of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigators0
SecondaryDuration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigator

For participants with objective response, DoR is the time from when the complete response (CR) or partial response (PR) (whichever is first) criteria are first met until progression disease (PD) or death due to any cause within the period of 2 scheduled tumor assessments (84 or 168 days) after the last tumor assessment, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
Time from the first dose of study drug until occurrence of PD, death due to any cause or last tumor assessment (assessed up to 218 days)

No measurements were reported for this outcome.

SecondaryProgression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigators

PFS is defined as the time (in months) from first administration of study intervention to the date of the first documentation of progression disease (PD) or death due to any cause within the period of 2 scheduled tumor assessments (84 or 168 days) after the last tumor assessment, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was to be estimated using Kaplan-Meier (KM) plots.

Time frame:
Time from the first dose of study drug until occurrence of PD, death due to any cause or last tumor assessment (assessed up to 218 days)
Reported as:
Median · months
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigators
monthsTepotinib + Cetuximab
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by InvestigatorsNA (NA to NA)
SecondaryOverall Survival (OS) Assessed by Investigators

OS is defined as the time (in months) from first administration of study intervention to the date of death. OS was to be estimated using Kaplan-Meier (KM) plots.

Time frame:
Time from first study treatment until death, assessed up to 218 days
Reported as:
Median · months
Overall Survival (OS) Assessed by Investigators
monthsTepotinib + Cetuximab
Overall Survival (OS) Assessed by InvestigatorsNA (NA to NA)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events that started or worsened after first dose of study intervention until 30 days after last dose. TEAEs included both serious and non-serious TEAEs. Treatment-related TEAEs is defined as reasonably related to the study intervention.

Time frame:
Time from first study treatment up to 30 days after the last dose, assessed up to 226 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs
ParticipantsTepotinib + Cetuximab
TEAEs2
Treatment-related TEAEs2
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Vital Signs

Vital sign assessment included assessments of height, weight, temperature, pulse rate, respiratory rate, and blood pressure. Clinical significance was determined by the investigator. Number of participants who had any clinically significant changes from baseline in vital signs were reported.

Time frame:
Time from first study treatment up to 30 days after the last dose, assessed up to 226 days
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs
ParticipantsTepotinib + Cetuximab
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs0
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters

Laboratory investigation included hematology, biochemistry, coagulation, routine urinalysis and other screening tests (Follicle-stimulating hormone (FSH) and estradiol, Serum or highly sensitive urine human chorionic gonadotropin (hCG) pregnancy test, Serology (HIV antibody, hepatitis B surface antigen \[HBsAg\], and hepatitis C virus antibody) and all of the safety labs were performed locally. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported.

Time frame:
Time from first study treatment up to 30 days after the last dose, assessed up to 226 days
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters
ParticipantsTepotinib + Cetuximab
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters0
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings

12-lead ECG recordings included heart rate and measures PR, QRS, QT and QTcF intervals. 12-lead ECG recordings were obtained after the participants have rested for at least 5 minutes in semi-supine or supine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported.

Time frame:
Time from first study treatment up to 30 days after the last dose, assessed up to 226 days
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings
ParticipantsTepotinib + Cetuximab
Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings0
SecondaryNumber of Participants With At Least 1 Postive Anti-Drug Antibodies (ADAs) for Cetuximab

Serum samples were analyzed by a validated electrochemiluminescence immunoassay method to detect the presence of antidrug antibodies (ADA). Number of participants with positive ADA were reported.

Time frame:
At Day 1 of cycle 1 (each cycle is of 21 days) and at End of Treatment (14 days after last dose, assessed up to 210 days)
Reported as:
Count of participants · Participants
Number of Participants With At Least 1 Postive Anti-Drug Antibodies (ADAs) for Cetuximab
ParticipantsTepotinib + Cetuximab
Number of Participants With At Least 1 Postive Anti-Drug Antibodies (ADAs) for Cetuximab0

Adverse events

Collected over Time from first study treatment up to 30 days after the last dose, assessed up to 226 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tepotinib + Cetuximab0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventTepotinib + Cetuximab
Skin toxicitySkin and subcutaneous tissue disorders1/2
Skin lesionSkin and subcutaneous tissue disorders1/2
oedema peripheralGeneral disorders1/2
diarrheaGastrointestinal disorders1/2
Mucosal inflammationGeneral disorders1/2
drug eruptionSkin and subcutaneous tissue disorders1/2
paronychiaInfections and infestations1/2
dry skinSkin and subcutaneous tissue disorders1/2
HypoalbuminaemiaMetabolism and nutrition disorders1/2
HypocalcaemiaMetabolism and nutrition disorders1/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tepotinib + Cetuximab
<=18 years0
Between 18 and 65 years1
>=65 years2
Sex: Female, Male
Sex: Female, Male(Participants)Tepotinib + Cetuximab
Female1
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tepotinib + Cetuximab
Hispanic or Latino0
Not Hispanic or Latino3
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tepotinib + Cetuximab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White3
More than one race0
Unknown or Not Reported0
08

Study locations

67 sites
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • Moores Cancer Center
    La Jolla, California 92093, United States
  • University of California, Los Angeles (UCLA)
    Santa Monica, California 90404, United States
  • Georgetown Lombardi Comprehensive Cancer Center
    Washington, District of Columbia 20007, United States
  • Mayo Clinic Hospital
    Jacksonville, Florida 322224-1865, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214-3728, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • North Shore-LIJ Monter Cancer Center
    Lake Success, New York 11042, United States
  • Allegheny-Singer Research Institute
    Pittsburgh, Pennsylvania 15212, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Scott & White Vasicek Cancer Treatment Center
    Temple, Texas 76508-0001, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109-1023, United States
  • Aurora Cancer Care - Milwaukee West
    Wauwatosa, Wisconsin 53226, United States
  • Antwerp University Hospital
    Antwerp, Belgium
  • UZ Leuven
    Leuven, Belgium
  • Universtity Hospital Brno
    Brno, Czechia
  • University Hospital Olomouc
    Olomouc, Czechia
  • Dept. of Oncology Faculty Hospital Motol
    Prague, Czechia
  • Hospital Na Bulovce
    Prague, Czechia
  • CHU Besançon Hôpital Jean Minjoz
    Besancon Cedex, France
  • University Hospital of Besançon
    Besançon, France
  • CHU Estaing
    Clermont Ferrand Cedex 1, France
  • CHU Estaing
    Clermont-Ferrand, France
  • CHU Hôpital Henri Mondor
    Créteil, France
  • Clinique Victor Hugo
    Le Mans Cedex 02, France
  • Clinique Victor Hugo
    Le Mans, France
  • CHU de Poitiers
    Poitiers, France
  • Curie Institute
    Saint Cloud, France
  • Institut Curie - René-Huguenin Hospital
    Saint-Cloud, France
  • Istituto Scientifico Romagnolo per lo Studio e la Cura die Tumori
    Meldona, Italy
  • Fondazione IRCCS - Istituto Tumori Milano
    Milan, Italy
  • Grande Ospedale Metropolitano Niguarda
    Milan, Italy
  • Istituto Europeo di Oncologia
    Milan, Italy
  • Istituto Nazionale Tumori, Fondazione G. Pascale Napoli
    Napoli, Italy
  • UOC Oncoematologia AOU Vanvitelli
    Napoli, Italy
  • Istituto Oncologico Veneto IRCCS
    Padova, Italy
  • Azienda Ospedaliero Universitaria Pisana-Ospedale Santa Chiara
    Pisa, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli
    Rome, Italy
  • Foundation IRCCS Casa Sollievo della Sofferenza
    San Giovanni Rotondo FG, Italy
  • Arkangelsk Clinical Oncological Dyspensary
    Arkhangelsk, Russian Federation
  • Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
    Chelyabinsk, Russian Federation
  • Kursk Regional Clinical Oncology Dispensary
    Kislino, Russian Federation
  • FSBI "National Medical Research Center of Oncology n.a. N.N. Blokhina" of the MoH of the RF
    Moscow, Russian Federation
  • Limited Liability Company Medicine 24/7
    Moscow, Russian Federation
  • Russian Cancer research center n.a. N.N. Blokhin
    Moscow, Russian Federation
  • Omsk Regional Oncology Dispensary
    Omsk, Russian Federation
  • LLC Clinica UZI 4D
    Pyatigorsk, Russian Federation
  • Pavlov First Saint Petersburg State Medical University
    St. Petersburg, Russian Federation
  • Tomsk National Research Medical Center
    Tomsk, Russian Federation
  • MKMC Medical City
    Tyumen, Russian Federation
  • SAHI Republican Clinical Oncology Dispensary
    Ufa, Russian Federation
  • Hospital Clinic de Barcelona
    Barcelona, Spain
  • Hospital del Mar
    Barcelona, Spain
  • VHIO Valle de Hebron Instituto de Oncologia
    Barcelona, Spain
  • H.U. Ramon y Cajal
    Madrid, Spain
  • HM-CIOCC
    Madrid, Spain
  • Hospital de Madrid Norte Sanchinarro
    Madrid, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital UNiversitario La Paz
    Madrid, Spain
  • H.U.Marqués de Valdecilla
    Santander, Spain
  • HUVirgen del Rocio
    Sevilla, Spain
  • Consorcio Hospital General Universitario de Valencia
    Valencia, Spain
  • Bristol Oncology Centre
    Bristol, United Kingdom
  • Beatson WJSCC
    Glasgow, United Kingdom
  • Guy's & St Thomas' NHS Foundation Trust
    London, United Kingdom
  • The Royal Marsden Hospital
    London, United Kingdom
  • The Royal Marsden Hospital
    Sutton, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union

Access criteria: Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.

Data sharing details ↗ · bit.ly

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Mar 2022, 13 months.

Results were first posted in Dec 2022, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Aug 17, 2020
StartActual
Jan 28, 2021
Primary completionActual
Mar 14, 2022
CompletionActual
Mar 31, 2022
Results first posted
Dec 22, 2022
Last update
Dec 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04515394
Responsible party
Sponsor
First posted
Aug 17, 2020
Start date
Jan 28, 2021
Primary completion
Mar 14, 2022
Completion
Mar 31, 2022
Results posted
Dec 22, 2022
Last update
Dec 22, 2022

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tepotinib · Cetuximab

Start the discussion